Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance

Clinical and Laboratory Haematology

Volumn 23, Issue 6, 2001, Pages 411-416

  Aboud, M R ^a   Ma, D D F ^b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Activated partial thromboplastin time (APTT); Resistance to activated protein C (APC); Russel viper venom time (RVVT); Venous thromboembolism (VTE)

Indexed keywords

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTICOAGULATION; ARTICLE; ASSAY; BLOOD ANALYSIS; BLOOD CLOTTING TIME; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITAL PATIENT; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MUTATION; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; VEIN THROMBOSIS; BLOOD; CASE REPORT; COHORT ANALYSIS; GENETICS; MIDDLE AGED; PROTHROMBIN TIME; RISK FACTOR; THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; CASE REPORT; COHORT STUDIES; FACTOR V; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; THROMBOEMBOLISM; VENOUS THROMBOSIS; HUMANS; MIDDLE AGED;

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN;

EID: 0035544370     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.2001.00421.x     Document Type: Article

References (23)

1. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation
2. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
3. Mutation in blood coagulation factor V associated with resistance to activated protein C
4. The impact of factor VIII in the fluctuation of APC response in healthy pregnant women
5. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese
6. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
7. Acquired activated protein C resistance in patients with thrombosis without the factor V, Q506 mutation
8. Assessment of haemostatic function: Follow up evaluation of abnormal screening coagulation tests and possible outcomes
9. Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis
10. Heparin kinetics in venous thrombosis and pulmonary embolism
11. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study. European Concerted Action on Thrombosis
12. Activated protein C resistance (APC) and inherited factor V (FV) missense mutation in patients with venous and arterial thrombosis in a haematology clinic
13. Thrombo-embolism in patients with abnormally short activated partial thromboplastin time
14. Preanalytical aspects of coagulation testing
15. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria
16. Risk factors for venous thrombosis: Prevalence, risk and interaction
17. Clinical significance of activated protein C resistance as a potential marker for hypercoaguable state
18. Resistance to activated protein C as a basis for venous thrombosis
19. The VITA project: Phenotypic resistance to activated protein C and FV Leiden mutation in the general population
20. Screening for the FV: Q 506 mutation - Evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis
21. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
22. Association of idiopathic venous thromboembolism with single point mutation at Arg 506 of factor V
23. Factor V Cambridge: A new mutation (Arg 306->Thr) associated with resistance to activated protein C